CNX-2006
CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer.
Product Specifications
CAS Number
1375465-09-0
Product Name Alternative
CNX2006 | CNX 2006 | CNX-2006.
Field of Research
Cell Biology
Purity
>98% (HPLC)
Solubility
DMSO : ≥ 52 mg/mL. 95.32 mM
Smiles
COc1c (Nc2ncc (c (Nc3cccc (NC (=O) C=C) c3) n2) C (F) (F) F) ccc (NC2CN (CCF) C2) c1
Molecular Formula
C26H27F4N7O2
Molecular Weight
545.53
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
N- (3- ((2- ((4- ((1- (2-fluoroethyl) azetidin-3-yl) amino) -2-methoxyphenyl) amino) -5- (trifluoromethyl) pyrimidin-4-yl) amino) phenyl) acrylamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
G-Protein Coupled Receptor 84 (GPR84, EX33, GPCR4, Inflammation-related G-protein Coupled Receptor) (MaxLight 750) discontinued
